ALL
2022
2021
2020~2015
Sep 10, 2018
SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US.
May 22, 2017
First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia
May 11, 2017
FDA Approves SyneuRx’ IND Application for Late Phase Clinical DeveloFirst Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trialpment of a Mild Dementia Treatment SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Apr 04, 2016
FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Dec 19, 2015
SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Cart
